Analysts expect Alliqua Biomedical Inc (NASDAQ:ALQA) to post earnings per share (EPS) of ($0.70) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical posted earnings of ($6.10) per share during the same quarter last year, which suggests a positive year over year growth rate of 88.5%. The business is expected to issue its next earnings report on Tuesday, March 6th.

On average, analysts expect that Alliqua Biomedical will report full year earnings of ($3.90) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will post earnings of ($2.10) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Alliqua Biomedical.

A number of research analysts have recently weighed in on the stock. HC Wainwright set a $20.00 price target on shares of Alliqua Biomedical and gave the company a “buy” rating in a report on Friday, August 11th. Zacks Investment Research upgraded shares of Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Tuesday, August 15th. Finally, ValuEngine upgraded shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $11.25.

Alliqua Biomedical (NASDAQ:ALQA) traded down $0.03 during trading on Friday, hitting $2.20. 60,243 shares of the stock were exchanged, compared to its average volume of 88,161. Alliqua Biomedical has a fifty-two week low of $1.99 and a fifty-two week high of $8.48.

A hedge fund recently raised its stake in Alliqua Biomedical stock. Renaissance Technologies LLC grew its stake in Alliqua Biomedical Inc (NASDAQ:ALQA) by 54.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 632,800 shares of the company’s stock after purchasing an additional 222,400 shares during the period. Renaissance Technologies LLC’s holdings in Alliqua Biomedical were worth $319,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Alliqua Biomedical Inc (ALQA) Will Post Earnings of -$0.70 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Get a free copy of the Zacks research report on Alliqua Biomedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Alliqua Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical Inc and related companies with's FREE daily email newsletter.